官方服务：
资源简介：
Hemagglutinin-inhibition (HAI) GMT.
应用场景：
创建时间：
2017-11-02
相关数据集
DataSheet_1_Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.pdf
IntroductionGiven the varying severity of coronavirus disease 2019 (COVID-19) and the rapid spread of Severe-Acute-Respiratory-Syndrome-Corona-Virus-2 (SARS-CoV-2), vaccine-mediated protection of part
NIAID Data Ecosystem120
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
Randomized, double-blind, placebo-controlled clinical trial of Ad26.COV2.S on 25 participants. Participants were randomized to receive single-shot and 2-shot vaccine regimens with either 5 X 1010 or 1
DataCite Commons2022-12-21 更新60
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
To determine the tolerability, immunogenicity and safety of the Ad26.COV2.S vaccine in humans.
NIAID Data Ecosystem30
Antibody responses to A/17/mallard/Netherlands/00/95 (H7N3) LAIV.
1The HAI antibody GMT after second vaccination was statistically significantly higher than pre–vaccination GMT (Wilcoxon Matched Pairs Test with Bonferroni adjustment: p = 0,0024); 2There was no stati
NIAID Data Ecosystem80
Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster
Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster
NCATS Open Data2021-08-20 更新30
